Source: Medicines Authority (MT) Revision Year: 2020 Publisher: MEDOCHEMIE LTD, 1-10 Constantinoupoleos street, 3011 Limassol, Cyprus
Toprisan, 50 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. White, round, biconvex, film-coated tablets with diameter 7mm. |
Each film-coated tablet contains itopride hydrochloride 50 mg.
Excipient with known effect: lactose. Each film-coated tablet contains 58.7 mg of lactose (as lactose monohydrate).
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Itopride |
Itopride activates the gastrointestinal propulsive motility by dopamine D2 receptors antagonistic action and acetylcholine esterase inhibitory action. Itopride activates acetylcholine release and inhibits its degradation. |
| List of Excipients |
|---|
|
Tablet core: Lactose monohydrate Film-coating: Hypromellose 2910 |
Clear PVC/PE/PVDC-Alu blisters and Clear PVC/PVDC-Alu blisters.
The available pack sizes are: 20, 30, 40 and 100 film-coated tablets.
Not all pack sizes may be marketed.
MEDOCHEMIE LTD, 1-10 Constantinoupoleos street, 3011 Limassol, Cyprus
MA032/09501
Date of first authorisation: 23rd May 2016
Date of renewal: 16th October 2020
| Drug | Countries | |
|---|---|---|
| TOPRISAN | Cyprus, Malta |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
